Clinical effect of propiverine in patients with urge or stress incontinence. Kobe University Incontinence Study Group.
The efficacy and tolerability of propiverine hydrochloride (20 mg/day) were evaluated in the treatment of a total of 49 Japanese patients (35 with urge incontinence and 14 with stress incontinence) in an open multicenter trial lasting 28 days. The effects on the frequency of urination, urinary incontinence, urinary urgency, and daily living activities were evaluated through the voiding diaries filled out by the patients. Moderate or greater degree of improvement was attained in micturition frequency by 52 and 54% of the patients with urge incontinence and with stress incontinence, respectively, in urinary urgency by 91 and 58%, in urinary incontinence by 97 and 71%, and in daily living activities by 94 and 64%. Although minor adverse reactions (5 patients) and abnormal values in blood chemistry (2 patients) were recorded in 7 patients, all of these patients completed the trial. These results suggest that propiverine hydrochloride is a safe and effective drug of choice for the treatment of not only urge incontinence but also stress incontinence in patients diagnosed in a clinical setting.
Okada
H
H
Department of Urology, Kobe University School of Medicine.
Sengoku
J
J
Gohji
K
K
Arakawa
S
S
Kamidono
S
S
D000203:Activities of Daily Living; D001561:Benzilates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D010276:Parasympatholytics / Q000627:therapeutic use*; D014549:Urinary Incontinence / Q000188:drug therapy*; D014550:Urinary Incontinence, Stress / Q000188:drug therapy*
D001561:Benzilates; D010276:Parasympatholytics; C015586:propiverine